Vaxart to Highlight Oral Vaccine Platform at BIO 2026, Taiwan Biotech Forum
Event summary
- Vaxart to present at BIO 2026 on June 23, 2026, and Taiwan Biotech Forum on June 21, 2026.
- CEO Steve Lo and CSO Sean Tucker, Ph.D., to discuss oral vaccine platform's advantages over traditional injections.
- Company developing oral vaccines for coronavirus, norovirus, influenza, and HPV.
- Vaxart's technology aims to eliminate needle injections and cold-chain logistics.
The big picture
Vaxart's focus on oral vaccines aligns with broader industry trends toward patient-friendly, logistically efficient healthcare solutions. The company's proprietary platform could disrupt traditional vaccine delivery methods, particularly in global health and pandemic preparedness. Success hinges on proving efficacy and scalability in clinical trials and securing partnerships for widespread distribution.
What we're watching
- Regulatory Approval
- The pace at which Vaxart can secure regulatory approvals for its oral vaccines will determine market entry timelines.
- Market Adoption
- Whether the company can convince healthcare providers and consumers to shift from traditional vaccines to oral alternatives.
- Competitive Positioning
- How Vaxart's technology stacks up against competitors developing similar oral or needle-free vaccine platforms.